Matt Sample from Cencora discusses current DSCSA developments on the rise for pharmacy businesses in 2026—namely small dispensers that have been under exemption.
Total Pharmacy
Latest News
Total Pharmacy Podcasts
All News
Advertisement
The event will explore how community pharmacy leaders can improve profitability, business resilience, as well as PBM and reimbursement challenges.
In this episode, host Taylor Watterson, PharmD, PhD, welcomes Mohammad Al Numan, BS, MS, a 2025-27 University of Illinois Chicago/Takeda Fellow in Health Economics and Outcomes Research.
Just before monumental PBM reform was signed into law, as well as a landmark settlement between the FTC and Express Scripts, the Department of Labor proposed its own set of PBM regulations.
Tennessee’s 2024 expansion of pharmacist's scope of practice authorizes independent prescribing and test-and-treat services, positioning pharmacists as primary care extenders in underserved communities.
Direct contracting can boost transparent drug pricing and help independent pharmacies earn fairly while patients save on generic medications.
As the pharmacy industry seemingly transforms in real-time, expert pharmacists and digital health experts explain how DTP models are paving a new path for drug distribution.
In their continued fight against major health care corporations, Senators Elizabeth Warren and Josh Hawley are aiming to delink ownership among PBMs, insurers, and wholesalers.
Timothy Aungst, PharmD; Ravi Patel, PharmD, MBA, MS; and Smit Patel, PharmD; provided much-needed nuance to the evolving nature of DTP pharmacy models in today’s landscape.
In what reports are calling a landmark settlement, Cigna agrees to make good on years of unfair business dealings that have affected patients and independent pharmacies.
Advertisement
This episode explores the “uphill climb” that many leaders in the modern pharmacy landscape experience and how experts like our hosts are navigating this challenge.
Timothy Aungst, PharmD; Ravi Patel, PharmD, MBA, MS; and Smit Patel, PharmD, share their insights on the emerging direct-to-patient pharmacy model.
TrumpRx drives Most-Favored-Nation drug pricing, cutting US costs for glucagon-like peptide-1, insulin, and fertility medications.
Anne Cassity, senior vice president of government affairs at NCPA, discusses the next moves of both PBMs and community pharmacy advocates following the signing of HR 7148.
As provisions begin rolling out over the next few years, community pharmacies will no longer be at the will of unfair reimbursement and contracting terms.
With President Trump’s signing of HR 7148, experts are now racing to get a grasp on the monumental shifts in pharmacy that will stem from this new legislation.
John C. Goodman explores TrumpRx's initiatives to lower prescription drug prices, emphasizing direct-to-consumer purchasing and innovative employer strategies for savings.
Independent pharmacies navigate a transformative 2026, benefiting from increased PBM accountability and transparency, fostering a more stable operational landscape.
As lawmakers continue to deliberate on HR 7148, pharmacy law expert, Jesse Dresser, Esq, joined Drug Topics to discuss its provisions related to PBMs.
Pharmacists enhance community health by providing vital services such as vaccinations and chronic disease management, despite facing reimbursement and recognition challenges.
If signed by President Trump in time to avoid a government shutdown, HR 7148 has potential to enforce significant change in the prescription drug supply chain.
Pharmacists transform health care by offering essential services, tackling the opioid crisis, and adapting to new initiatives for better patient outcomes.
This episode explores important insights on PBM reform and what pharmacies can look out for throughout 2026.
As more prescription drugs move to OTC, the pharmacist’s role in their communities are continuing to shift as well.
In part 2, Alyssa Billingsley, PharmD, explores some of the recent switches that made waves in the US and how they impact pharmacy operations as well as patient outcomes.
Community pharmacies continue to operate in unchartered territory regarding Medicare drug price negotiations as the new IRA statute becomes an unavoidable reality for business operations.
Advertisement
Advertisement